Registrational study of novel formulation of thiotepa
Latest Information Update: 14 Aug 2020
At a glance
- Drugs Thiotepa (Primary)
- Indications Graft-versus-host disease
- Focus Registrational; Therapeutic Use
- 14 Aug 2020 New trial record
- 10 Aug 2020 According to a CASI Pharmaceuticals media release, the Companys partner for the novel formulation of Thiotepa plans to begin the China registration study in 2021.